Efficacy of Osimertinib in Patients With Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Patients must be ≥18 years.
• Provision of fully informed consent prior to any study specific procedures.
• Advanced or metastatic lung squamous cell carcinoma confirmed by histology or cytology.
• According to the RECIST 1.1 standard, the patient must have at least one measurable lesion.
Locations
Other Locations
China
Hunan Cancer hospital
RECRUITING
Changsha
Contact Information
Primary
Yongchang C Zhang, MD
zhangyongchang@csu.edu.cn
+8613873123436
Backup
Nong Yang, MD
yangnong0217@163.com
+8613055193557
Time Frame
Start Date: 2021-01-01
Estimated Completion Date: 2025-09-15
Participants
Target number of participants: 100
Related Therapeutic Areas
Sponsors
Leads: Hunan Province Tumor Hospital